Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Blood (2023) 142 (Supplement 1): 610.

https://doi.org/10.1182/blood-2023-180107

Published: 2023

Journal Articles

Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Anthony N. Audino, Stanton Goldman, Matthew J. Barth, Jessica Hochberg, Ana C. Xavier, Bruce Shiramizu, Qiuhu Shi, Lauren Harrison, Jackie Basso, Javier Oesterheld, Kenneth Matthew Heym, Richard A. Drachtman, Paul Harker-Murray, Sherrie L. Perkins, Rodney R. Miles, Mitchell S. Cairo

Blood (2023) 142 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2023-181756

Published: 2023

Journal Articles

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Paul Harker-Murray, Christine Mauz-Körholz, Thierry Leblanc, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Bradford S. Hoppe, Julie Lisano, Stephen Francis, Mariana Sacchi, Peter D. Cole, Richard A. Drachtman, Kara M. Kelly, Stephen Daw

Blood (2023) 141 (17): 2075–2084.

https://doi.org/10.1182/blood.2022017118

Published: 2023

Includes: Supplemental data

Journal Articles

Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, Retrospective Study of Patients Treated with Voxelotor

Caterina P Minniti, Henny H. Billett, Daniel McMahon, Modupe Idowu, Nirmish Shah, Richard A. Drachtman, Archana Sharma, Alexander Glaros, Maureen Okam Okam Achebe, Alecia C Nero, Susanna Curtis, Biree Andemariam

Blood (2022) 140 (Supplement 1): 8276–8277.

https://doi.org/10.1182/blood-2022-169334

Published: 2022

Journal Articles

Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor: A Multicenter, Retrospective Study

Biree Andemariam, Maureen Achebe, E. Leila Jerome Clay, Richard A. Drachtman, Archana Sharma, Alecia C Nero, Ifeyinwa Osunkwo, Sharada Sarnaik, Modupe Idowu, Nirmish Shah, Susanna A Curtis, Caterina Minniti

Blood (2021) 138 (Supplement 1): 3100.

https://doi.org/10.1182/blood-2021-153459

Published: 2021

Journal Articles

Utilizing Medical Students As Patient Mentors: An Intervention to Improve Transition Readiness in Young Adults with Sickle Cell Disease

Adrienne Viola, PhD MPH, Richard A. Drachtman, MD, Amanda Kaveney, MD, Ashwin Sridharan, MD, Beth Savage, MSN, ANP, Jerlym S. Porter, PhD MPH, Katie Devine, PhD MPH

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-142021

Published: 2020

Journal Articles

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Jessica C. Hochberg, MD, Stanton Goldman, MD, Matthew J. Barth, MD, Qiuhu Shi, PhD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Jackie Basso, Yaya Chu, PhD, Humayun Islam, Perry Gerard, MD MBA, FACR, Javier Oesterheld, MD, Kenneth Matthew Heym, MD, Ivan I. Kirov, MD, Richard A. Drachtman, MD, Paul Harker-Murray, MD PhD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Bruce Shiramizu, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139464

Published: 2020

Journal Articles

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Clark Brown, Carolyn Hoppe, Adlette Inati, Miguel R. Abboud, Winfred Wang, MD, Robert Liem, MD, Gerald Woods, Lewis L. Hsu, Victor R. Gordeuk, MD, Connie Piccone, Richard A. Drachtman, Erica Fong, Sandra Dixon, Margaret Tonda, PharmD, Carla Washington, Joshua Lehrer-Graiwer

Blood (2018) 132 (Supplement 1): 509.

https://doi.org/10.1182/blood-2018-99-117510

Published: 2018

Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw

Blood (2018) 132 (Supplement 1): 927.

https://doi.org/10.1182/blood-2018-99-111279

Published: 2018

Journal Articles

Changes in Serum TARC Predict PET Response Among Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Treated with Brentuximab Vedotin and Gemcitabine: A Report from the Children's Oncology Group

Peter D Cole, MD, Menachem Spira, MD, Kathleen M McCarten, MD, Terzah M Horton, MD, Quinglin Pei, PhD, Monika Metzger, Richard A Drachtman, MD, Kara M. Kelly, MD

Blood (2017) 130 (Supplement 1): 2798.

https://doi.org/10.1182/blood.V130.Suppl_1.2798.2798

Published: 2017

Journal Articles

Preliminary Results Of a Pharmacokinetic Study Of Intravenous Asparaginase Erwinia Chrysanthemi Following Allergy To E Coli -Derived Asparaginase In Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma

Lynda M. Vrooman, MD, Ivan I. Kirov, MD, Zoann E. Dreyer, MD, Michael Kelly, MD, PhD, Nobuko Hijiya, MD, Patrick Brown, MD, Richard A. Drachtman, MD, Yoav H Messinger, MD, A. Kim Ritchey, MD, Gregory A. Hale, MD, Kelly Maloney, MD, Paul V. Plourde, MD, Lewis B. Silverman, MD

Blood (2013) 122 (21): 3904.

https://doi.org/10.1182/blood.V122.21.3904.3904

Published: 2013

Journal Articles

Novel Homozygous VHL Mutation in Exon 2 (413C>T:P138L) Is Associated with Congenital Polycythemia, Elevated Level of RUNX1/AML1 Transcript, but Not with the Cancer.

Lucie Piterkova, PhD, Felipe R Lorenzo V, M.D., PhD., Hari Vankalayapati, MPharm., PhD., Richard A. Drachtman, MD, Josef T. Prchal, MD

Blood (2012) 120 (21): 2081.

https://doi.org/10.1182/blood.V120.21.2081.2081

Published: 2012

Journal Articles

AHOD0321: A COG Phase 2 Study of Weekly Gemcitabine and Vinorelbine for Children with Recurrent or Refractory Hodgkin Disease.

Peter D. Cole, MD, Tanya M. Trippett, MD, Richard A. Drachtman, MD, Pedro de Alarcon, MD, Lu Chen, Cindy L. Schwartz, MD

Blood (2007) 110 (11): 2318.

https://doi.org/10.1182/blood.V110.11.2318.2318

Published: 2007

Journal Articles

Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse.

Peter D. Cole, MD, Richard A. Drachtman, MD, Angela K. Smith, Margaret Masterson, MD, John Glod, Md, PhD, Barton A. Kamen, MD, PhD

Blood (2006) 108 (11): 1860.

https://doi.org/10.1182/blood.V108.11.1860.1860

Published: 2006

Journal Articles

Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity.

Peter D. Cole, MD, Richard A. Drachtman, MD, Margaret Masterson, MD, Angela Shenkerman, APN, Angela K. Smith, Benadette Makori, Barton A. Kamen, MD, PhD

Blood (2004) 104 (11): 1950.

https://doi.org/10.1182/blood.V104.11.1950.1950

Published: 2004

NARROW

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Multicenter Pilot Trial of Intrathecal Liposomal Cytarabine Combined with FAB Chemoimmunotherapy with Reduced Doxorubicin in CAYA with Mature De-Novo B-NHL

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults

Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, Retrospective Study of Patients Treated with Voxelotor

Real-World Experience of Patients with Sickle Cell Disease Treated with Voxelotor: A Multicenter, Retrospective Study

Utilizing Medical Students As Patient Mentors: An Intervention to Improve Transition Readiness in Young Adults with Sickle Cell Disease

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Changes in Serum TARC Predict PET Response Among Pediatric Patients with Relapsed or Refractory Hodgkin Lymphoma Treated with Brentuximab Vedotin and Gemcitabine: A Report from the Children's Oncology Group

Preliminary Results Of a Pharmacokinetic Study Of Intravenous Asparaginase Erwinia Chrysanthemi Following Allergy To E Coli -Derived Asparaginase In Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma

Novel Homozygous VHL Mutation in Exon 2 (413C>T:P138L) Is Associated with Congenital Polycythemia, Elevated Level of RUNX1/AML1 Transcript, but Not with the Cancer.

AHOD0321: A COG Phase 2 Study of Weekly Gemcitabine and Vinorelbine for Children with Recurrent or Refractory Hodgkin Disease.

Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse.

Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only